SCOTT PINEGAR: Open Payments
NPI 1174009567 · ARVADA, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,990 in 153 payments from 19 companies in 2025. Trend: 2023 $4,075 · 2024 $3,325 · 2025 $2,990
Food & beverage: $2,986Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $621 |
| Gilead Sciences, Inc. | 19 | $466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $346 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $224 |
| Madrigal Pharmaceuticals | 8 | $199 |
| Janssen Biotech, Inc. | 8 | $175 |
| QOL Medical, LLC | 11 | $161 |
| PFIZER INC. | 11 | $143 |
| Regeneron Healthcare Solutions, Inc. | 6 | $126 |
| GENZYME CORPORATION | 4 | $96 |
Products named: RINVOQ, DUPIXENT, XIFAXAN, REZDIFFRA, ENTYVIO, TREMFYA, EOHILIA, Sucraid.
Industry payments across CO — which companies pay providers there.
